HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES 4-YEARS AFTER TREATMENT WITH VALOCTOCOGENE ROXAPARVOVEC
FP Caretaa, B Madanb, MC Ozeloc, G Kenetd, S Choue, S Pipef, A Leavittg, A Ruizh, E Dashiell-Ajei, J Mahlanguj
a Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil
b Guy's and St Thomas'NHS Foundation Trust, London, UK
c Centro de Hematologia e Hemoterapia (Hemocentro), Department of Internal Medicine, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
d The National Hemophilia Center and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University
e Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
f Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA
g Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, USA
h National Bleeding Disorders Foundation, Oakland Park, FL, USA
i BioMarin Pharmaceutical Inc., Novato, CA, USA
j Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa
Ver másLido
405
Vezesque se leu este artigo
156
Total PDF
249
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 Junho | 3 | 2 | 5 |
| 2025 Maio | 45 | 7 | 52 |
| 2025 Abril | 34 | 8 | 42 |
| 2025 Mar�o | 41 | 19 | 60 |
| 2025 Fevereiro | 32 | 15 | 47 |
| 2025 Janeiro | 21 | 22 | 43 |
| 2024 Dezembro | 21 | 24 | 45 |
| 2024 Novembro | 37 | 37 | 74 |
| 2024 Outubro | 15 | 22 | 37 |
